Intervention not reported
Ofatumumab No direct evidence · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…
It is very uncertain whether the intervention changes ofatumumab No direct evidence (very low certainty).
1 finding from 1 review
OR 1.52 [0.89, 2.57]
Studies not reported
Very low
Intervention not reported
Ozanimod No direct evidence · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…
It is very uncertain whether the intervention changes ozanimod No direct evidence (very low certainty).
1 finding from 1 review
OR 1.5 [0.85, 2.64]
Studies not reported
Very low
Intervention not reported
Ponesimod No direct evidence · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…
It is very uncertain whether the intervention changes ponesimod No direct evidence (very low certainty).
1 finding from 1 review
OR 1.24 [0.66, 2.35]
Studies not reported
Very low
Intervention not reported
Teriflunomide (Direct evidence; 2 RCTs; 2253 participants) · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…
It is very uncertain whether the intervention changes teriflunomide (Direct evidence; 2 RCTs; 2253 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Placebo · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Caries arrestment at the surface level · Children and adults with active dental caries (aged 1-50; mostly preschool/school children with primary dentition)
SDF probably makes little to no difference to surface-level caries arrestment versus other methods (moderate certainty).
1 finding from 1 review
Adverse effects (tooth staining and other side effects) · Children and adults with active dental caries (aged 1-50; mostly preschool/school children with primary dentition)
SDF commonly causes black staining of arrested lesions; only mild, transient adverse events were reported, with no major adverse events (ungraded).
1 finding from 1 review
CA VI activity · Children (age about 2-9 years) across the 7 meta-analyzed activity samples; excludes Kivela 1999 adults (18-24 years), qualitative only…
Salivary/biofilm CA VI activity is significantly higher in individuals with dental caries than in caries-free individuals (SMD 0.894, 95% CI 0.386 to 1.392; not GRADE-rated).
1 finding from 1 review
Depression Hospital Anxiety and Depression Scale (HADS) or Beck Inventory Score (HADS score range from 0 to 21 and Beck Inventory Score range from 0 to 63) · Women with non‐metastatic breast cancer
1 finding from 1 review
Anxiety · Women with non‐metastatic breast cancer
1 finding from 1 review
Mood disturbance Profile of mood state (higher score indicates more mood disturbance, score range from 0 to 200) · Women with non‐metastatic breast cancer
1 finding from 1 review
QoL · Women with non‐metastatic breast cancer
1 finding from 1 review
Stress 1 month · Women with non‐metastatic breast cancer
1 finding from 1 review
Overall survival (12 months) · weight reduction in obesity to improve survival in women with endometrial cancer
1 finding from 1 review
Overall survival (24 months) · weight reduction in obesity to improve survival in women with endometrial cancer
It is very uncertain whether summary of findings table ‐ Lifestyle intervention changes overall survival (24 months) compared with usual care compared to placebo (very low certainty).
1 finding from 1 review
Adverse events – musculoskeletal · weight reduction in obesity to improve survival in women with endometrial cancer
It is very uncertain whether summary of findings table ‐ Lifestyle intervention changes adverse events – musculoskeletal compared with usual care compared to placebo (very low certainty).
1 finding from 1 review
Cancer‐specific survival (24 months) (Number of cancer‐related deaths) · weight reduction in obesity to improve survival in women with endometrial cancer
1 finding from 1 review
Weight loss (change in kg weight) · weight reduction in obesity to improve survival in women with endometrial cancer
1 finding from 1 review
Quality of life: FACT‐G (12 months) · weight reduction in obesity to improve survival in women with endometrial cancer
1 finding from 1 review
Time to death from any cause Range of · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors showed no clear difference in time to death from any cause Range of compared with any first‐line chemotherapy (moderate certainty).
1 finding from 1 review